Avaliaçäo crítica do sevelamer no tratamento da hiperfosfatemia em pacientes com insuficiência renal crônica

Sesso, Ricardo; Ferraz, Marcos B.
Rev. Assoc. Med. Bras. (1992) ; 49(1): 103-108, jan.-mar. 2003. tab
Artigo em Português | LILACS | ID: lil-332722

Documentos relacionados

  1. The clinical management of hyperphosphatemia.
  2. [Critical appraisal of sevelamer for the treatment of hyperphosphatemia in patients with chronic renal failure].
  3. Association of klotho gene polymorphism and the regulation of calcium-phosphate metabolism disorders in patients with end-stage renal disease.
  4. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
  5. The phosphate binder equivalent dose.
  6. [Evolution in vitamin D treatment after debut of sevelamer hydrochloride in chronic renal failure patients].
  7. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
  8. Sevelamer.
  9. [Experience with sevelamer in peritoneal dialysis].
  10. [Sevelamer hydrochloride prevents ectopic calcification of blood vessels].